Is Truly Ra Medical Systems a Reliable Penny Stock to Have?

The shares of commercial-stage medical gadget maker Ra Medical Systems (RMED) have tumbled 92.7% in rate over the past year as a result of investor concerns surrounding the business’s bad economic health and wellness. Also, provided the unpredictability surrounding the FDA’s authorization of its DABRA catheter laser system, the concern comes to be, is the penny stock a winner now? Keep reading, allow’s learn.

Medical tool firm Ra Medical Systems, Inc. (RMED – Get Score) in Carlsbad, Calif., is styles, establishes, and markets excimer lasers to deal with vascular illness. The firm has actually made substantial progress in essential initiatives, including its DABRA technology laser system as well as atherectomy essential medical research study. Nevertheless, the stock RMED has declined 86.8% in cost over the past 6 months and also 92.7% over the past year, mirroring investor concerns over its unsatisfactory profits as well as incomes growth as well as the sale of its dermatology organization.

Closing yesterday’s session at $0.42, the stock is currently trading 95.7% below its 52-week high of $9.82, indicating bearish sentiment.

While the commercial-stage medical gadget firm has actually submitted a 510( k) application with the U.S. Fda (FDA) for its DABRA catheter, its commercialization prospects remain uncertain up until its item gets approval from the FDA. In addition, the stock’s unfavorable productivity might make investors distressed.

Marketing Shares

Last month, RMED priced an underwritten public offering of systems of its ordinary shares, including warrants to buy as much as 27.6 million shares of the common stock and also pre-funded warrants to buy up to 14.47 shares of ordinary shares. The medical gadget manufacturer expects roughly $12.1 million in gross earnings from the offering.

Divestiture of Dermatology Business

Top 10 Stocks for 2022
In the third quarter, RMED finished the sale of its Pharos dermatology service for internet earnings of roughly $3.5 million. This was done as a part of the business’s strategies to focus its resources on the market for medical tools to treat peripheral artery illness (PAD). However, the divestiture could adversely impact the medical device manufacturer’s revenues as well as price structure in the near term and also cause RMED’s stock price to tumble even more.

Bleak Profitability

The company’s trailing-12-month ROA and cash from procedures are unfavorable 100.6% as well as $31.33 million, specifically. Furthermore, its trailing-12-month gross profit margin, ROE and also ROTC are unfavorable 18.9%, 115%, and 67%, respectively. And also its 0.12% possession turn over ratio is 65.2% less than the 0.34% market standard.

Faltering Financials
RMED’s internet profits from proceeding operations came in at $5,000 for the third quarter, ended Sept. 30, 2021, versus $68,000 in the third quarter of 2020. Its gross loss stood at $24,000 for the quarter, while operating loss came in at $7.39 million. Moreover, its bottom line amounted to $4.3 million, while its loss per share was available in at $0.67. RMED reported a negative adjusted EBITDA of $6.95 million versus $6.06 million in the prior-year quarter. And also its overall operating costs grew 2.1% year-over-year to $7.15 million during this period.

POWR Scores Mirror Bleak Leads

RMED has an overall D score, which converts to Market in our POWR Rankings system. The POWR Scores are calculated by taking into consideration 118 unique factors, with each factor heavy to an ideal degree.

Our proprietary rating system likewise examines each stock based on eight distinctive categories. RMED has an F quality for High quality. This mirrors the stock’s negative ROA as well as capital from operations.

The company has a D grade in Energy, consistent with its rate decrease over the past 6 months. Additionally, it has an F quality for Stability, which is in sync with its reasonably high beta of 1.65.

Past the grades I have highlighted, one can have a look at extra RMED scores for Belief, Growth, as well as Worth below. Amongst the 166 stocks in the D-rated Medical– Devices & Tools industry, RMED is rated # 119.


Experts anticipate RMED’s EPS to remain unfavorable this year. While its efforts to establish DABRA catheters bode well, its negative earnings margin as well as insufficient monetary strength could cause its shares to decrease further. In addition, the uncertainty surrounding the regulative clearance and commercialization of its DABRA laser system can elevate financiers’ problems. So, we assume it is ideal prevented currently.

Exactly How Does Ra Medical Systems (RMED) Compare To its Peers?

While RMED has an overall D (Market) rating in our exclusive score system, one could wish to consider having a look at its sector peers, Fonar Corporation (FONR – Get Ranking), Electromed, Inc. (ELMD – Get Rating), as well as Abbott Laboratories (ABT – Obtain Rating), having an A (Solid Buy) ranking.